Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...

Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...

It has also brought up new questions about whether the sky-high expectations for Mounjaro and Zepbound are justified. Let’s understand the company’s strengths and weaknesses to better analyze ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

Nvidia's strength might be a worthwhile macroeconomic ... that management hopes will drive the pharma's growth in 2025 -- Zepbound and Mounjaro. This issue may just be a blip, and that's certainly ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

The Zepbound® formulation had a strength of 2.5 mg tirzepatide administered once via injection with the subject monitored over the same eight-day total duration. Blood samples were taken multiple ...